Citadel Advisors
ZYME icon

Citadel Advisors’s Zymeworks ZYME Stock Holding History

Citadel Advisors’s Portfolio ZYME Stock Details ZYME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.18M Buy
87,100
+72,800
+509% +$1.72M ﹤0.01% 5906
2025
Q4 		$377K Sell
14,300
-30,600
-68% -$667K ﹤0.01% 9665
2025
Q3 		$767K Sell
44,900
-6,500
-13% -$93K ﹤0.01% 8129
2025
Q2 		$645K Buy
51,400
+300
+0.6% +$3.57K ﹤0.01% 8025
2025
Q1 		$609K Buy
51,100
+40,700
+391% +$555K ﹤0.01% 8045
2024
Q4 		$152K Sell
10,400
-10,000
-49% -$140K ﹤0.01% 10865
2024
Q3 		$256K Buy
20,400
+7,000
+52% +$76.2K ﹤0.01% 9626
2024
Q2 		$114K Sell
13,400
-7,900
-37% -$70.3K ﹤0.01% 10729
2024
Q1 		$224K Sell
21,300
-3,600
-14% -$40K ﹤0.01% 10094
2023
Q4 		$259K Sell
24,900
-5,400
-18% -$43K ﹤0.01% 9456
2023
Q3 		$192K Buy
30,300
+9,200
+44% +$67.9K ﹤0.01% 9985
2023
Q2 		$182K Sell
21,100
-5,600
-21% -$50.1K ﹤0.01% 10034
2023
Q1 		$241K Sell
26,700
-12,800
-32% -$112K ﹤0.01% 9830
2022
Q4 		$310K Sell
39,500
-49,100
-55% -$345K ﹤0.01% 9238
2022
Q3 		$545K Sell
88,600
-4,000
-4% -$24.1K ﹤0.01% 8276
2022
Q2 		$491K Sell
92,600
-6,500
-7% -$39.3K ﹤0.01% 8698
2022
Q1 		$649K Buy
99,100
+84,200
+565% +$750K ﹤0.01% 8761
2021
Q4 		$244K Sell
14,900
-2,600
-15% -$54.2K ﹤0.01% 11420
2021
Q3 		$508K Sell
17,500
-6,500
-27% -$216K ﹤0.01% 9822
2021
Q2 		$833K Sell
24,000
-2,000
-8% -$63.5K ﹤0.01% 8834
2021
Q1 		$821K Sell
26,000
-13,800
-35% -$561K ﹤0.01% 8592
2020
Q4 		$1.88M Buy
39,800
+6,900
+21% +$320K ﹤0.01% 5466
2020
Q3 		$1.53M Sell
32,900
-12,200
-27% -$419K ﹤0.01% 5223
2020
Q2 		$1.63M Buy
45,100
+15,700
+53% +$578K ﹤0.01% 4930
2020
Q1 		$1.04M Buy
29,400
+22,200
+308% +$909K ﹤0.01% 5264
2019
Q4 		$327K Buy
+7,200
New +$262K ﹤0.01% 7459

Other funds holding ZYME

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Citadel Advisors's ZYME Position: Q1 2026 in Review

Citadel Advisors increased its Zymeworks (ZYME) stake by 350% in Q1 2026, buying an estimated $21.2M and bringing the position to 1,150,018 shares worth $28.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1907.

Citadel Advisors first reported a position in ZYME in Q4 2017 and has held it in 30 quarters since. The position peaked at $33.1M in Q2 2020. 211 funds tracked by Wall St. Rank hold ZYME as of Q1 2026.

  • Citadel Advisors held 1,150,018 shares of Zymeworks worth $28.8M as of Q1 2026.
  • Citadel Advisors bought 894,667 Zymeworks shares in Q1 2026, an estimated $21.2M.
  • Zymeworks made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #1907 holding.
  • Citadel Advisors first reported a position in Zymeworks in Q4 2017 and has held it in 30 quarters since.
  • Citadel Advisors's Zymeworks position peaked at $33.1M in Q2 2020.
  • 211 funds tracked by Wall St. Rank held Zymeworks as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.